

IFW



**HAND DELIVERED**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of: Zeldis

Confirmation No.: To Be Assigned

Application No.: 10/578,809 (U.S. national stage  
of PCT/US2004/037084)

Group Art Unit: To Be Assigned

Int. Filing Date: November 4, 2004

Examiner: To Be Assigned

For: METHODS OF USING AND  
COMPOSITIONS COMPRISING A JNK  
INHIBITOR FOR THE TREATMENT  
AND MANAGEMENT OF ASBESTOS-  
RELATED DISEASES AND DISORDERS

Attorney Docket No.: 9516-186-999  
(CAM: 501872-999471)

**INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.56 and 1.97**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. §§ 1.56 and 1.97 to inform the United States Patent and Trademark Office ("Office") of all information coming to the attention of each individual associated with the filing and prosecution of the above-identified application that is or may be related to patentability of the claimed invention, Attorneys for Applicants hereby invite the Examiner's attention to references **A01-A26**, **B01-B15** and **C01-C37**, which are listed on the accompanying "List of References Cited By Applicant."

Copies of references **B01-B15** and **C01-C37** are submitted herewith. Copies of References **A01-A26**, which are either United States patents or patent application publications, are not being submitted pursuant to 37 C.F.R. § 1.98(a)(2)(ii), unless requested by the Office.

Identification of the listed references is not to be construed as an admission that such references are available as "prior art" against the subject application.

Applicants request that the Examiner review all the references identified on the attached accompanying "List of References Cited By Applicant", and that they be made of record in the file history of the above-identified application.

As this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits, Applicants estimate that no fee is required. Should a fee be required, please charge the required fee to Jones Day Deposit Account No. 50-3013.

Respectfully submitted,

*Anthony M. Insogna, Res. No. 35,203*  
*By: Michael J. Bruner, Res. No. 47,458*


Date: July 19, 2006

By: Michael J. Bruner (Reg. No. 47,458)  
For: Anthony M. Insogna (Reg. No. 35,203)

**JONES DAY**  
12750 High Bluff Drive, Suite 300  
San Diego, California 92130  
(858) 314-1130

Enclosures

**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)



**ATTY. DOCKET NO.**

9516-186-999

**APPLICATION NO.**

10/578,809

**APPLICANT**

Zeldis

**INT. FILING DATE**

November 4, 2004

**ART UNIT**

To Be Assigned

**U.S. PATENT DOCUMENTS**

*Examiner Initials		Document Number	Date mm/dd/yyyy	Name of Patentee or Applicant of Cited Document	
	A01	3,095,415	06/25/1963	Staeuble et al.	
	A02	3,522,263	07/28/1970	Guenthard et al.	
	A03	3,541,110	11/17/1970	Bell et al.	
	A04	4,879,252	11/07/1989	Komatsu	
	A05	5,985,867	11/16/1999	Rodgers et al.	
	A06	6,114,333	09/05/2000	Davis et al.	
	A07	6,361,760	03/26/2002	Murata et al.	
	A08	6,555,539	04/29/2003	Reich et al.	
	A09	6,589,950	07/08/2003	Collingwood et al.	
	A10	6,897,231	05/24/2005	Bhagwat et al.	
	A11	2003/0073732	04/17/2003	Sakata et al.	
	A12	2003/0187052	10/02/2003	Muller et al.	
	A13	2003/0203926	10/30/2003	Kois et al.	
	A14	2003/0220330	11/27/2003	Yoshitaka et al.	
	A15	2004/0067953	04/08/2004	Stein et al.	
	A16	2004/0072888	04/15/2004	Bennett et al.	
	A17	2004/0077877	04/22/2004	Bhagwat et al.	
	A18	2004/0092562	05/13/2004	Sakata et al.	
	A19	2004/0106634	06/03/2004	Satoh et al.	
	A20	2004/0127536	07/01/2004	Bhagwat et al.	
	A21	2004/0176434	09/09/2004	Bennett et al.	
	A22	2004/0242578	12/02/2004	Bolloor et al.	
	A23	2005/0009876	01/13/2005	Bhagwat et al.	
	A24	2005/0107457	05/19/2005	Bhagwat et al.	
	A25	2006/0004043	01/05/2006	Bhagwat et al.	
	A26	2006/0004080	01/05/2006	Bhagwat et al.	

NYJD-1626715v1

**EXAMINER**

**DATE CONSIDERED**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)

**ATTY. DOCKET NO.**

9516-186-999

**APPLICATION NO.**

10/578,809

**APPLICANT**

Zeldis

**INT. FILING DATE**

November 4, 2004

**ART UNIT**

To Be Assigned

**FOREIGN PATENT DOCUMENTS**

*Examiner Initials		Foreign Patent Document Country Code, Number, Kind Code (if known)	Date mm/dd/yyyy	Name of Patentee or Applicant of Cited Document		
	B01	CS 146 895 1	11/12/1971	Arient (w/ English language abstract)		
	B02	DE 1266763	04/25/1968	Kalle A. G. (w/ English language abstract)		
	B03	FR 2 024 807	09/04/1970	Ciba Societe Anonyme (w/ English language abstract)		
	B04	FR 2 167 626	08/24/1973	Badische Anilin & Soda-Fabrik AG (w/ corresponding English language patent GB 1404969)		
	B05	FR 2 336 708	07/22/1977	Hoechst Aktiengesellschaft (w/ corresponding English language patent GB 1576217)		
	B06	FR 2 401 915	03/30/1979	Ciba-Geigy AG (w/ corresponding English language patent GB 2003477)		
	B07	GB 1 489 280	10/19/1977	Chugai Seiyaku Kabushiki Kaisha		
	B08	GB 2 345 486	07/12/2000	Glaxo Group Limited		
	B09	WO 89/10924	11/16/1989	National Research Dev. Corp.		
	B10	WO 95/21864	08/17/1995	Ludwig Institute for Cancer Research		
	B11	WO 99/17798	04/15/1999	Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V.		
	B12	WO 01/12609	02/22/2001	Signal Pharmaceuticals, Inc.		
	B13	WO 02/10137	02/07/2002	Signal Pharmaceuticals, Inc.		
	B14	WO 02/46170	06/13/2002	Signal Pharmaceuticals, Inc.		
	B15	WO 02/066450	08/29/2002	Signal Pharmaceuticals, Inc.		

**NON PATENT LITERATURE DOCUMENTS**

*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
	C01	ABERLE, 1991, "High-resolution computed tomography of asbestos-related diseases," Semin. Roentgenol. 26(2):118-131	
	C02	ADAM, et al., 1999, "Coagulation and Fibrinolysis in patients undergoing operation for ruptured and nonruptured infrarenal abdominal aortic aneurysms," Vascular Surgery 30(4):641-650	
	C03	AHARINEJAD et al., 1995, "CSF-1 treatment promotes angiogenesis in the metaphysis of osteopetrotic (toothless, tl) rats," Bone 16(3):315-224	
	C04	AMES et al., 1987, "An integrated concept of amebicidal action: electron transfer and oxy radicals," Free Radical Biol. Med. 3:85-96	

NYJD-1626715v1

**EXAMINER**

**DATE CONSIDERED**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)**ATTY. DOCKET NO.**

9516-186-999

**APPLICATION NO.**

10/578,809

**APPLICANT**

Zeldis

**INT. FILING DATE**

November 4, 2004

**ART UNIT**

To Be Assigned

**NON PATENT LITERATURE DOCUMENTS**

*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
C05		ANDRONATI, 1994, [Synthesis of 1-[4-phenyl-1-piperazinyl]butyl]-1,2-dihydro-3H-1, 4-benzodiazepin-2-ones and -1H-indazoles and their affinity for benzodiazepine receptors], Dopov. Akad. Nauk. Ukr., 8: 126-131 (with English language abstract)	
C06		ARYA et al., 1977, "Synthesis of Nitroheterocycles: Part IV*-Synthesis of 1-Substituted 4-Nitroisoquinolines, 5- & 6- Nitroindazoles & 6-Nitrobenzimidazoles," Indian J. Chem. Sect. B 15B(7):625-628	
C07		BAAS et al., 1997, "Photodynamic therapy as adjuvant therapy in surgically treated pleural malignancies," Br. J. Cancer 76(6):819-826	
C08		BOEHM et al., 2000, "Novel Inhibitors of DNA Gyrase: 3D Structure Based Biased Needle Screening, Hit Validation by Biophysical Methods, and 3D Guided Optimization. A Promising Alternative to Random screening," J. Med. Chem. 43(14): 2664-2674	
C09		BUCK, 1993, "Total Synthesis of Peruvianine, A Phenolic 7-oxoaporphine alkaloid of Telitoxicum Peruvianum," Heterocycles 36(11):2489-2495	
C10		BUSCHMANN et al., 1998, "GM-CSF promotes collateral artery growth via prolongation of macrophage survival," J. Mol. & Cell. Card. 30(6):A126	
C11		FUJIMURA et al., 1986, "Synthesis and Pharmacological Activities of 2,3-Dihydro-1-H-pyrazolo-[1,2-a]indazolium Derivatives," 106(11): 1002-1007 (with English language abstract)	
C12		GALUSHKO et al., 1977, "Pyrazoloanthrone derivatives I. Reactivity of 3-aminopyrazoloanthrone," English translation from Khimiya Geterotsiklicheskih Soedinenii 7:956-961	
C13		GVON et al., 1994, [Amino-imino tautomerism and intramolecular cyclization of 4, 9-diamino-1, 10-anthraquinone-1-tosylimines], Dokl. Akad. Nauk, 334:465-468 (with English language abstract)	
C14		HARTLEY et al., 1988, "Characteristics of the interaction of anthrapyrazole anticancer agents with deoxyribonucleic acids: structural requirements for DNA binding, intercalation, and photosensitization," Mol. Pharmacol. 33:265-271	
C15		ITO et al., 1997, "Monocyte chemotactic protein-1 increases collateral and peripheral conductance after femoral artery occlusion," Circ. Res. 80(6):829-837	
C16		IVANOVA et al., 1997, "XPS investigation of electronic structure of pyrazoloanthrone and its derivatives," Poverkhnost 4-5:193-201	
C17		JONES et al., 1983, "The Reaction of 4-Alkyl-3-thiosemicarbazides with B-Haloketones," Heterocycl. Chem. 20(5): 1359-1361	
C18		JUDSON, 1992, "The anthrapyrazoles: a new class of compounds with clinical activity in breast cancer," Semin. Oncol. 19:687-694	
C19		KAISER, 1997, "New therapies in the treatment of malignant pleural mesothelioma," Semin. Thorac Cardiovasc. Surg. 9(4):383-390	
C20		KAWAKAMI et al., 2000, "NaH-Mediated One-Pot Cyclocondensation of 6-Nitroquinoline with Aromatic Hydrazone to Form [1.2.4]Triazino[6,5-f]quinolines and/or Pyrazolo[3,4-f]quinolines" Organic Letters 2(3): 413-415	
C21		MILLER et al., 1992, "Rounded atelectasis: diagnosis by fine-needle aspiration cytology," Diagnostic Cytopath. 8(6):617-620	
C22		PATEL et al., 1999, "Unsymmetrical cyclic ureas as HIV-1 Protease Inhibitors: Novel Biaryl Indazoles as P2/P2' Substituents," Bioorganic and Medicinal Chemistry Letters 9(22): 3217-3220	
C23		PEACOCK et al., 2000, "Asbestos-related benign pleural disease," Clin. Radiol. 55(6):422-432	

NYJD-1626715v1

**EXAMINER****DATE CONSIDERED**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)	<b>ATTY. DOCKET NO.</b> 9516-186-999	<b>APPLICATION NO.</b> 10/578,809
	<b>APPLICANT</b> Zeldis	
	<b>INT. FILING DATE</b> November 4, 2004	<b>ART UNIT</b> To Be Assigned

	C24	PFOERTNER et al., 1982, "1 H-Indazoles Obtained by Photolysis of 2-Aminophenylketon-0-(ethoxycarbonyl) oximines and of 3,1,4-Benzoxadiazephene-2(1 H)-ones," <i>Helv. Chim. Acta</i> 65(3): 798-806 (with English language abstract)	
	C25	SHOWALTER et al, 1988, "Design, tumor biology, and biochemical pharmacology of anthrapyrazoles," <i>Bioact. Mol.</i> V1:201-243	
	C26	SHOWALTER et al., 1984, "5-[(Aminoalkyl)amino]-substituted anthra[1,9-cd]pyrazol-6(2H)-ones as novel anticancer agents. Synthesis and biological evaluation", <i>J. Med. Chem.</i> 27:253-255	
	C27	SHOWALTER et al., 1987, "Anthrapyrazole anticancer agents. Synthesis and structure-activity relationships against murine leukemias," <i>J. Med. Chem.</i> 30:121-131	
	C28	SINGH et al., 1978, "Reactions of 2,2'-ethylene-bis-anthrapyrazolone", <i>Indian J. Chem.</i> 16B:100-102	
	C29	SOKOLYUK et al., 1993, "Synthesis and photochemical properties of peri-phenoxy derivatives of 6H-anthra[1,9-cd]-6-pyrazolone (pyrazolanthrone)," <i>J. Organic Chem. of the USSR</i> 1993, 28(10, Part 2):1761-1768, English translation from <i>Zhurnal Organicheskoi Khimii</i> 28:2193-2200 (1992)	
	C30	STAPLES, 1992, "Computed tomography in the evaluation of benign asbestos-related disorders," <i>Radiologic Clinics of N. Amer.</i> 30(6):1191-1207	
	C31	SUGARBAKER et al., 1996, "Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma. Results in 120 consecutive patients," <i>Ann. Surg.</i> 224(3):288-294	
	C32	TURTON, 1980, "Pleural effusions," <i>Br. J. Hosp. Med.</i> 23(3):239-240; 244, 246-247, 249	
	C33	VAN HAARST et al., 2002, "Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma," <i>Br J Cancer.</i> 86(3):342-345	
	C34	VASILEVSKY et al., 1996, "Cyclocondensation of activated ortho-chloroarylacetylenes with hydrazine: a novel route to substituted indazoles," <i>Mendeleev. Commun.</i> 3: 98-99	
	C35	WALSER et al., 1974, "Nucleophilic Displacement of Aromatic Fluorine, Part 1, Synthesis of Benzisoxazoles," <i>J. Heterocycl. Chem.</i> 11(6): 885-888	
	C36	WRZECIONO et al., 1985, "Part 14: On the behaviour of 5-Chloro-2-Nitroindazole Against Aliphatic and Cyclic Amines," <i>Pharmazie</i> 40(2):105-108 (with English language abstract)	
	C37	WRZECIONO et al., 1992, "Part 33: 5-Flouroindazole derivatives," <i>Pharmazie</i> 47(1): 22-24 (with English language abstract)	

NYJD-1626715v1

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	